HOME >> BIOLOGY >> NEWS
Claudin-1: A potential biomarker for colon cancer progression

Disruption of proteins expressed at the junctures between cells (known as tight junctions) is a hallmark of cancer cell invasion and spread (metastasis). Recent studies have shown that changes in the family of tight junction proteins known as claudins occur during tumor initiation and growth, however no causal link between claudin expression and cancer has been demonstrated.

In a study appearing online on June 16 in advance of print publication in the July 1 issue of the Journal of Clinical Investigation, Punita Dhawan and colleagues from Vanderbilt University report increased expression of claudin-1 in human primary colon carcinomas and metastases. They also found that instead of being normally expressed in the cell membrane, claudin-1 was instead located in the colon cancer cell nucleus and cytoplasm. Those cancer cells that metastasized from the primary tumor site were found to express the highest levels of claudin-1 and also exhibited a greater degree of claudin-1 mislocalization. Using genetically manipulated colorectal cancer cells, the authors demonstrate a role for claudin-1 in the regulation of cellular transformation, tumor growth, and spread and identify, in part, the cellular pathways involved in claudin-1 overexpression.

These observations raise the possibility that claudin-1 may be exploited as a potential biomarker for colon cancer progression and may also provide new opportunities for therapeutic intervention.


'"/>

Contact: Brooke Grindlinger
press_releases@the-jci.org
212-342-9006
Journal of Clinical Investigation
16-Jun-2005


Page: 1

Related biology news :

1. UCF research links proteins, stem cells and potential Alzheimers treatment
2. Picky eating potentially perilous for bats
3. Scientists take next step in understanding potential target for ovarian cancer treatment
4. Nanoparticles hitchhike on red blood cells: a potential new method for drug delivery
5. Weill Cornell team identifies potential new cancer drug target
6. LIAI researchers identify a potential role for retinoic acid in autoimmune and inflammatory diseases
7. GM field trials underestimate potential for cross-pollination
8. New study suggests potential for a broadly-protective HIV vaccine
9. Hamilton College researchers discover molecules with potential to treat breast cancer
10. 8 plants from South Africa may hold potential for treating high blood pressure
11. TXNIP -- regulator of glucose homeostasis and potential diabetes drug target and more

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:11/14/2019)... (PRWEB) , ... November 13, 2019 , ... Personalized ... the first patients in an FDA approved clinical trial for stem cell treatment ... the formation of the company as a subsidiary of VetStem Biopharma. , In July ...
(Date:11/12/2019)... ... 12, 2019 , ... The Arnold and Mabel Beckman Foundation ... institutions for its Instrumentation Grant for Advanced Light-Sheet Microscopy and Data Science ... for the acquisition of instrumentation, development and maintenance; support for data science collaborations ...
(Date:11/9/2019)... ... November 08, 2019 , ... StageBio ... histology, pathology, biomarker development, and archiving services for the biopharmaceutical, medical device ... Histo-Scientific Research Laboratories (HSRL), Vet Path Services (VPS) and Tox Path Specialists ...
Breaking Biology News(10 mins):
(Date:11/5/2019)... , ... November 04, 2019 ... ... of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene ... cell line development technology, GPEx® Boost. The technology enhances Catalent’s proven GPEx ...
(Date:11/2/2019)... , ... October 31, 2019 , ... ... Adaptive Biotechnologies in a live webinar on Friday, November 15, ... immuno-oncology. , Immunosequencing, the science of profiling T-cell receptors (TCRs) and B-cell ...
(Date:10/29/2019)... ... 28, 2019 , ... CaroGen Corporation , a biotechnology company, today announced ... Professor Jack R Wands, MD, of Brown University , Dr. Steve Projan, ... Mor, MD, PhD, of Wayne State University, formerly a professor at Yale University School ...
(Date:10/22/2019)... ... ... nQ Medical, Inc. of Cambridge, MA, was recognized in the top 5 ... at a showcase event yesterday in Los Angeles. nQ competed against 3,500 early-stage U.S. ... near-term growth projections to be named one of the most fundable companies in America. ...
Breaking Biology Technology:
Cached News: